Guilin Sanjin(SZ:002275)2025-06-08 14:42Financial Performance - In 2024, the company achieved total revenue of 2,193.99 million CNY, a growth of 1.03% compared to 2023's 2,171.60 million CNY [1] - The total profit reached 643.94 million CNY, marking a 24.24% increase from 518.28 million CNY in the previous year [1] - Net profit attributable to shareholders was 521.53 million CNY, up 23.79% from 421.30 million CNY year-on-year [1] - In Q1 2025, the net profit excluding non-recurring gains and losses was 97.67 million CNY, an 11.61% increase from 87.52 million CNY in Q1 2024 [1] Biopharmaceutical Development - The biopharmaceutical sector is a key component of the company's dual strategy, facing a challenging environment with long R&D cycles and high investment risks [1] - The company has seen significant growth in business development and customer resource accumulation in 2023, although it still falls short of scale production requirements [1] - Ongoing projects in the pipeline are still in the R&D phase, with limited revenue from technical services, leading to a smaller overall revenue scale [1] - The company is optimizing costs and expenses while focusing on promising projects, such as the BC006 monoclonal antibody injection, which is nearing completion of Phase I clinical trials [1] Inventory Management - The company has upgraded its inventory management system, utilizing a BI intelligent analysis system to enhance efficiency [2] - A scientific "finished product inventory standard model" has been established to balance market demand dynamics and cost control [2] - The overall inventory level has improved significantly, maintaining a healthy inventory cycle of 1.5 to 2 months, which supports operational quality and cost optimization [2] Dividend Policy - The company is committed to providing stable returns to investors and has maintained a consistent cash dividend policy since its listing [2] - For the 2024 annual equity distribution plan, the company proposes a cash dividend of 3.5 CNY per 10 shares, totaling 206 million CNY [2] - The company plans to continue its cash dividend policy in 2025, barring any special funding needs [2] Basic Drug Directory - The adjustment of the national essential drug directory is led by relevant government departments, and the company has not engaged in any application processes during this period [2] - The timeline for the announcement of the new essential drug directory remains uncertain, as it depends on the progress of the adjustment work by the authorities [2]